Track topics on Twitter Track topics that are important to you
Germany's Boehringer Ingelheim has started a new 12-week multinational trial to evaluate the safety, tolerability and pharmacokinetics (PK) of add-on treatment with pirfenidone to background therapy w...
(MedPage Today) -- Pooled data show significant reduction with pirfenidone
New data has shown Esbriet (pirfenidone) from Roche’s Genentech unit can reduce risk of death in idiopathic…
What questions remain about the recently approved medications for the treatment of idiopathic pulmonary fibrosis -- pirfenidone and nintedanib. Current Opinion in Pulmonary Medicine
Roche today announced that new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS...
Roche today announced that new Esbriet (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 Septe...
A phase III clinical trial of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) in Japan has revealed that pirfenidone attenuated the decline in vital capacity (VC) and improved progres...
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with a median survival of 2-5 years and limited treatment options. In 2008, pirfenidone became the first drug to be approved for ...
Idiopathic pulmonary fibrosis (IPF) is a primary lung disorder that scars distal airspaces and has a prognosis similar to many aggressive cancers. After decades of failed clinical trials, two drugs (n...
treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical cl...
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a lifethreatening event and one of the important endpoints in clinical trials involving IPF. Despite this, there has been little evaluat...